POLD1-related polyposis and colorectal cancer syndrome

disease
On this page

Summary

POLD1-related polyposis and colorectal cancer syndrome (MONDO:0100351) is a cancer caused by POLD1 (GenCC Definitive), with 1 cohort gene (1 CIViC-evidence somatic driver).

At a glance

  • Classification: Cancer
  • Causal gene: POLD1 (GenCC Definitive)
  • Cohort genes: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namePOLD1-related polyposis and colorectal cancer syndrome
Mondo IDMONDO:0100351
GARD0026151
Is cancer (heuristic)yes

Data availability: 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorpolypneoplastic polyppolyposisPOLD1-related polyposis and colorectal cancer syndrome

Related subtypes (3): polyposis, intestinal, scattered and discrete, gastric adenocarcinoma and proximal polyposis of the stomach, POLE-related polyposis and colorectal cancer syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 15 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

GeneintOGen roleCancer typesCIViC
POLD1LoFBRCA,ESCACIViC #4384

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
POLD1DefinitiveAutosomal dominantPOLD1-related polyposis and colorectal cancer syndrome15

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
POLD1Orphanet:363649Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome
POLD1Orphanet:440437Familial colorectal cancer Type X
POLD1Orphanet:447877Polymerase proofreading-related polyposis

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
POLD1HGNC:9175ENSG00000062822P28340DNA polymerase delta catalytic subunitgencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
POLD1DNA polymerase delta catalytic subunitAs the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor18.3×0.121

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
POLD1Transcription factorno2.7.7.7DNA-dir_DNA_pol_B_exonuc, DNA-dir_DNA_pol_B_multi_dom, DNA-dir_DNA_pol_B

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
mucosa of transverse colon1
primordial germ cell in gonad1
ventricular zone1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
POLD1134ubiquitousmarkermucosa of transverse colon, ventricular zone, primordial germ cell in gonad

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
POLD14,000

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
POLD1P283406

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 18. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Processive synthesis on the lagging strand11142.0×0.003POLD1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)1815.7×0.003POLD1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)1815.7×0.003POLD1
Polymerase switching1815.7×0.003POLD1
Removal of the Flap Intermediate1815.7×0.003POLD1
Processive synthesis on the C-strand of the telomere1761.3×0.003POLD1
Telomere C-strand (Lagging Strand) Synthesis1761.3×0.003POLD1
Cytosolic iron-sulfur cluster assembly1761.3×0.003POLD1
Removal of the Flap Intermediate from the C-strand1634.4×0.003POLD1
PCNA-Dependent Long Patch Base Excision Repair1519.1×0.003POLD1
Gap-filling DNA repair synthesis and ligation in GG-NER1439.2×0.004POLD1
Polymerase switching on the C-strand of the telomere1423.0×0.004POLD1
Recognition of DNA damage by PCNA-containing replication complex1380.7×0.004POLD1
Termination of translesion DNA synthesis1346.1×0.004POLD1
Dual Incision in GG-NER1259.6×0.005POLD1
HDR through Homologous Recombination (HRR)1190.3×0.006POLD1
Gap-filling DNA repair synthesis and ligation in TC-NER1178.4×0.006POLD1
Dual incision in TC-NER1173.0×0.006POLD1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
DNA replication proofreading15617.3×0.001POLD1
error-free translesion synthesis13370.4×0.001POLD1
nucleotide-excision repair, DNA gap filling12808.7×0.001POLD1
base-excision repair, gap-filling11123.5×0.002POLD1
DNA synthesis involved in DNA repair1936.2×0.002POLD1
fatty acid homeostasis1936.2×0.002POLD1
DNA biosynthetic process1802.5×0.002POLD1
DNA-templated DNA replication1561.7×0.003POLD1
response to UV1366.4×0.004POLD1
cellular response to UV1295.6×0.004POLD1
DNA replication1165.2×0.007POLD1
DNA repair163.8×0.016POLD1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
POLD100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
POLD18Binding:8

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
POLD12.7.7.7DNA-directed DNA polymerase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1POLD1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
POLD18

Clinical trials & evidence

Clinical trials

Clinical trials: 0.